It is believed that the Cannabinoid receptor type 1 (CB1), part of the endocannabinoid system, plays an important role in the regulation of appetite. The increased stimulation of CB1 receptors can lead to weight gain in animals and humans. Development of an antagonist for the CB1 receptor has drawn considerable attention recently as a treatment of obesity as exemplified by rimonabant, a CB1 antagonist currently under FDA review. We synthesized a number of diaryl cyclohexene carboxamides based on the structure of rimonabant. The SAR of their CB1 binding affinity, selectivity over CB2, and in vivo efficacy will be described.